Welcome to our dedicated page for Sernova Biotherapeutics news (Ticker: SEOVF), a resource for investors and traders seeking the latest updates and insights on Sernova Biotherapeutics stock.
Sernova Biotherapeutics reports developments tied to its clinical-stage regenerative medicine programs, including the Cell Pouch Bio-hybrid Organ being developed for type 1 diabetes. Company news centers on clinical and regulatory updates, research collaborations involving donor cells, stem-cell derived islet-like clusters and immunosuppression approaches, and the advancement of its bio-hybrid organ platform.
Recurring updates also cover Sernova's capital structure, including private placements, debt settlements, convertible debentures, warrant issuances and debt-to-equity conversions. Governance items include annual meeting results, board composition and shareholder voting matters.
Sernova Corp. addressed misleading claims from dissident shareholders regarding its board renewal process and proxy battle. The company asserts that its management has positioned Sernova for value creation, evidenced by a 17% year-to-date share price increase, outperforming the 8% decline in the Nasdaq XBI biotech index. Despite challenges in the biotech sector, Sernova's clinical trial advancements and technology partnerships, specifically with Evotec SE, are poised to enhance shareholder value. Upcoming milestones include clinical trial updates for type-1 diabetes and a hypothyroid disease program. Sernova ended Q1 2023 with cash resources of $45.6 million, providing a solid financial foundation for ongoing and future projects.
Sernova Corp. (OTCQB:SEOVF) announced that an abstract will be presented at the American Diabetes Association 83rd Scientific Sessions from June 23-26, 2023, in San Diego, CA. The abstract titled "Islet Allotransplantation into Pre-vascularized Sernova Cell Pouch" will be delivered on June 24 at 5:15 PM PT. This significant presentation showcases early results from the University of Chicago concerning Sernova's innovative Cell Pouch System, which aims to provide a functional cure for insulin-dependent diabetes. The study may impact future treatment approaches and is part of Sernova's broader strategy to develop cell therapies for chronic diseases.
Sernova Corp. (OTCQB:SEOVF) announced its first pre-clinical data presentation regarding the Cell Pouch with Evotec’s iPSC-derived islet-like clusters for type 1 diabetes (T1D). The presentation is set for April 24, 2023, at the 4th International Pancreas and Islet Transplant Association Summit in Cambridge, Massachusetts. This collaboration aims to develop a scalable process for manufacturing insulin-producing cells from induced pluripotent stem cells (iPSCs) for cell therapy. Sernova’s ongoing Phase 1/2 study demonstrates the potential of the Cell Pouch System as a functional cure for T1D.
Sernova Corp. (OTCQB:SEOVF) announced the implantation of the third patient with its advanced 10-chamber Cell Pouch in a Phase 1/2 trial for type 1 diabetes treatment. The company expects to report interim data from the second patient cohort in Q4 2023.
The new cohort includes up to seven patients, and the protocol is designed to optimize islet transplant efficacy. The 10-channel Cell Pouch offers over 50% more capacity than previous models, aiming to reduce severe hypoglycemic episodes and insulin dependency. The interim results from this trial phase are highly anticipated, as they may indicate pivotal advancements in diabetes treatment.
Sernova Corp. (OTCQB: SEOVF) announced its participation in two major conferences: the 35th Annual Roth Conference from March 12-14, 2023, and the Oppenheimer 33rd Annual Healthcare Conference from March 13-15, 2023. Dr. Philip Toleikis, CEO, will engage in one-on-one investor meetings and present a fireside chat on March 13, 2023, at 4:00 PM PT. Additionally, Sernova revealed that 20,136,918 warrants expired unexercised on March 1, 2023, leaving 303,332,686 shares outstanding. The company focuses on developing a 'functional cure' for insulin-dependent diabetes through its Cell Pouch System.
Sernova Corp. (OTCQB: SEOVF) has announced promising results from a preclinical study showing that thyroid auto-transplantation into its Cell Pouch can restore hormone production post-thyroidectomy. This advancement aims to eliminate the need for lifelong hormone replacement therapy in patients who have undergone thyroid removal, which affects over 150,000 individuals annually in the U.S. The company is now engaging with regulatory authorities to initiate clinical trials, highlighting a significant step toward offering a new treatment option for hypothyroidism.
Sernova Corp. (OTCQB: SEOVF) announced advancements in its collaboration with Evotec SE, focusing on a pioneering off-the-shelf cell therapy for Type 1 Diabetes (T1D). The combination of Evotec’s iPSC-derived islet-like clusters with Sernova’s Cell Pouch aims for a 2024 regulatory filing for clinical trials. Key achievements include scalable islet cluster manufacturing and successful T1D preclinical model results, showcasing long-term insulin independence. The partnership aims to provide a potential functional cure for insulin-dependent diabetes, reducing patient reliance on daily insulin.
Sernova Corp. has announced a leadership transition, with Dr. Philip Toleikis stepping down as CEO to become Chief Technology Officer. The company is actively searching for a new CEO to guide its next growth phase, particularly as it aims to expand in US capital markets. Dr. Toleikis has led the firm for 13 years, developing its Cell Pouch System for treating chronic diseases like diabetes. The transition aims to ensure continued advancements in the company’s technology and therapies. The executive search firm Slone Partners is assisting in the recruitment process.
Sernova Corp. (OTCQB:SEOVF) announced significant advancements in its clinical trial for type 1 diabetes. With the recent implantation of the 10-channel Cell Pouch in the second cohort of its Phase 1/2 study, the company enhances capacity and aims for optimized dosing. Patient recruitment has surged due to a new strategy, and interim data is expected in 2023. This trial aims for key efficacy endpoints, potentially paving the way for a pivotal Phase 3 program. The Cell Pouch System aims to provide a functional cure for diabetes, targeting insulin independence for patients.
Sernova Corp. (OTCQB:SEOVF) announced its participation in the Stifel Healthcare Conference on November 15-16, 2022, in New York. Dr. Philip Toleikis, President & CEO, will present on November 15 at 9:45 AM. Sernova is focused on developing regenerative cell therapeutic technologies for chronic diseases, primarily through its Cell Pouch System, aimed at providing a 'functional cure' for insulin-dependent diabetes. The company is also involved in partnerships to enhance its therapies, including a strategic collaboration with Evotec for iPSC-based beta cell replacement.